Report ID: 10085836 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Definition of Cardiac Implants
Cardiac implants are implantable medical devices that can be used to correct arrhythmias caused by heart disorders and heart failure in patients. Cardiovascular implants must remain within the patient's body to ensure the normal functioning of the heart and blood vessels. A cardiac implant can be used in several different conditions such as arrhythmias, acute myocardial infarction, congestive heart failure as well as other heart conditions. Ventricular arrhythmias are life-threatening heartbeats caused by fast, irregular heartbeats in people who have advanced heart disease, heart failure, and certain genetic arrhythmias. Patients with these conditions might require an implantable cardioverter defibrillator (ICD), which delivers an electric shock to restore a normal heartbeat.
Global Cardiac Implants Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~8% |
|
Base Year Market Size (2022) |
~ USD 33 Billion |
|
Forecast Year Market Size (2035) |
~ USD 79 Billion |
|
Regional Scope |
|
Global Cardiac Implants Market Highlights Over 2023 - 2035
The global cardiac implants market is estimated to garner revenue of ~USD 79 Billion by the end of 2035 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2035. Further, the market generated revenue of approximately USD 33 Billion in the year 2022. The growth of the market can be attributed to a surge in the number of patients suffering from heart diseases such as cardiovascular diseases (CVDs), heart attacks, arrhythmia, and inherited heart conditions. According to the World Health Organization, approximately 17.9 million people died in 2019 from CVDs, which represent 32 percent of deaths worldwide. In the diagnosis and treatment of heart disease and heart failure, cardiac implants play an essential role in monitoring patients' heart rates and disease progression.
GET A SAMPLE COPY OF THIS REPORT
Cardiac implants also known as cardiovascular implants are a technique under which devices are placed in the chest to detect the fluctuations in the heartbeats of patients dealing with heart failure or heart rhythm disorders. Depending on the device type used to monitor and control regular heartbeats, the main types of cardiac implants are heart valves, pacemakers, coronary stents, and ventricular assist devices. Furthermore, the use of the new cardiac implant devices for patient treatment has been approved by the regulatory bodies and it is anticipated to surge the market size of cardiac implants. As per the U.S. Food & Drug Administration, seven new implant medical devices were approved in 2021 by FDA.
Global Cardiac Implants Market: Growth Drivers and Challenges
Growth Drivers
-
An Increase in the Number of Geriatric Population– As the body ages, physical changes occur that weaken the heart muscles owing to a reduction in body activation. Several studies have shown that the elderly are significantly more likely to develop bradyarrhythmia as a result of syncope than younger patients. Therefore, there is a significant increase in the use of cardiac implantable electronic devices among the elderly, which is projected to drive market growth over the forecast period. In 2021, globally there were approximately 747,238,580 people aged 60 or older, according to a recent report by the World Bank. This number is expected to increase shortly.
-
Increasingly Deteriorating Living Standards– Cigarette smoking increases the risk of heart disease owing to the presence of toxic substances that affect the body’s blood and heart vessels. According to the World Health Organization, nearly 1.9 million people die yearly from tobacco-induced heart disease.
-
Growing Number of Cardiac Surgeries Being Performed – It was observed that in 2019, approximately 92,500 operations were classified as heart surgery procedures. Moreover, over 7.5 million cardiac surgeries have been recorded in the database of the Society of Thoracic Surgeons.
-
High Healthcare Spending Associated With Advanced Healthcare Devices – rising demand for advanced healthcare devices for treating and diagnosing heart diseases has led to an increase in hospital medical expenditure. As per the World Bank, global current health expenditure has risen to 9.83 percent of the total GDP in 2019 from 9.34 percent in 2000.
-
Increased Risk of Cardiovascular Disease- A fast-paced lifestyle and a change in dietary habits are contributing factors to cardiovascular disease. The World Health Organization reported that 17.9 million people died from cardiovascular disease worldwide in 2019. 85% of deaths were caused by heart attacks and strokes. Increasing cardiac surgery rates are expected to boost cardiac implant growth as heart failure becomes more common.
Challenges
-
Risk Associated With Pacemaker Implantation
Having a pacemaker or having surgery for a pacemaker can involve complications, such as an infection at the place of the pacemaker's implantation. A patient may experience swelling, bruising, or bleeding at the site of their pacemaker, particularly if they are taking blood thinners. Hence, this factor is projected to restrict the market growth in the coming years.
-
Rising Infections from Cardiac Implant Devices
-
Complicated Procedure to be Followed During Cardiac Implantation
The global cardiac implant market is segmented and analyzed for demand and supply by device type into heart value, pacemakers, coronary stents, ventricular assist devices, and others. The pacemaker segment is anticipated to hold the largest share over the forecast period. This can be attributed to the rise in the number of patients going for pacemaker implantation, and the need to accelerate the heartbeat following heart attacks and surgeries. As per the Journal of the American Heart Association, nearly, 3 million patients around the globe have pacemakers, and every year, approximately 600,000 pacemakers are implanted.
Global Cardiac Implants Market Regional Synopsis
The North American cardiac implants market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035 owing to the rise in heart diseases such as CVDs, and heart failure coupled with the surge in adoption of cardiac implant surgery. The implant monitors the heart rate and sends an electric signal to the heart to beat at a steady pace. According to the Centers for Disease Control and Prevention, one person dies every 34 seconds from cardiovascular diseases in the United States. Moreover, Diabetes, high LDL (bad) cholesterol, and high blood pressure are the leading risk factors for heart disease and stroke. Moreover, according to the same source, there are expected to be 12.1 million atrial fibrillation sufferers in the United States by 2030. Consequently, an increase in cardiovascular disease prevalence is expected to have a positive effect on cardiac implant usage in the region over the forecast period.
Market Segmentation
Our in-depth analysis of the global cardiac implants market includes the following segments:
|
By Application |
|
|
By End User |
|
|
By Device Type |
|
Key Companies Dominating the Global Cardiac Implants Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global cardiac implants market that are included in our report are Boston Scientific Corporation, Terumo Corporation, LivaNova PLC, Abbott, Medtronic, AMG International, Stryker Corporation, Koninklijke Philips N.V., SynCardia Systems, LLC, Edwards Lifesciences Corporation, and others.
Global Cardiac Implants Market: Latest Developments
-
4 July 2022: Terumo Corporation announced the first commercial implant of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device in the United States after the recent approval by the US Food and Drug Administration (FDA) for the treatment of patients suffering from the aortic arch disease.
-
December 2021: Boston Scientific Corporation announced the induction of the MODULAR ATP clinical trial to assess the performance, effectiveness, and safety of the mCRM Modular Therapy System. Moreover, the CRM System is made up of two cardiac rhythm management (CRM) devices that work together to coordinate therapy: the EMBLEMTM MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWERTM Modular Pacing System (MPS).
Frequently Asked Question
The market is segmented by device type, end-users, application, and by region.
The pacemaker segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10085836 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
